Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity.
Biomaterials
; 217: 119308, 2019 10.
Article
em En
| MEDLINE
| ID: mdl-31279103
Most of current influenza virus vaccines fail to develop a strong immunity at lung mucosae (site of viral entry) due to sub-optimal vaccination protocols (e.g. inactivated virus administered by parenteral injections). Mucosal immunity could be improved by using locally-delivered vaccines containing appropriate adjuvants. Here we show, in a mouse model, that inclusion of silver nanoparticles (AgNPs) in virus-inactivated flu vaccine resulted in reduction of viral loads and prevention of excessive lung inflammation following influenza infection. Concomitantly, AgNPs enhanced specific IgA secreting plasma cells and antibodies titers, a hallmark of successful mucosal immunity. Moreover, vaccination in the presence of AgNPs but not with gold nanoparticles, protected mice from lethal flu. Compared with other commercial adjuvants (squalene/oil-based emulsion) or silver salts, AgNPs stimulated stronger antigen specific IgA production with lower toxicity by promoting bronchus-associated lymphoid tissue (BALT) neogenesis, and acted as a bona fide mucosal adjuvant.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prata
/
Imunoglobulina A
/
Vacinas contra Influenza
/
Adjuvantes Imunológicos
/
Imunidade nas Mucosas
/
Influenza Humana
/
Nanopartículas Metálicas
/
Tecido Linfoide
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Biomaterials
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
França